Research Laboratory, Dong-A Pharmaceutical Company, Giheung, Yongin, Gyeonggi 446-905, Korea.
J Sex Med. 2010 Jul;7(7):2564-71. doi: 10.1111/j.1743-6109.2010.01858.x. Epub 2010 May 26.
Radical prostatectomy is the treatment of choice for prostate cancer patients. Despite the introduction of nerve-sparing surgical techniques, its success is not entirely guaranteed and the majority of patients report compromised erectile function following surgical procedures.
This study was performed to investigate the effect of repeated dosing of udenafil, a novel phosphodiesterase type 5 inhibitor, on penile hypoxia and fibrosis induced by bilateral cavernous nerve resection (BCNR) in rats.
Thirty male Sprague-Dawley rats (300-320 g) were used in this study. The animals were divided into three groups; group I consisted of sham-operated animals (N = 10), animals in group II underwent BCNR alone (N = 10), and animals in group III were orally treated with 10 mg/kg udenafil b.i.d. for 8 weeks following BCNR (N = 10).
The expression of transforming growth factor-beta1, hypoxia-inducible factor-1 alpha, endothelial nitric oxide synthase, neuronal nitric oxide synthase, and endothelin B receptor in penile tissue was examined at gene level. Additionally, erectile function, measured by intracavernous pressure (ICP), and pathological changes in the corpus cavernosum were examined.
While fibrosis, apoptosis, and the expression of TGF-beta1, HIF-1 alpha, and ET(B) were significantly increased, and the expression of eNOS and nNOS were significantly decreased in group II, compared with the sham-operated animals, repeated dosing of udenafil significantly ameliorated these changes. Erectile function was profoundly impaired in animals that underwent BCNR alone, and udenafil treatment significantly attenuated this impairment as measured by ICP.
These results demonstrate that long-term administration of udenafil ameliorates penile hypoxia and fibrosis induced by cavernous nerve resection. This study also suggests the potential beneficial role of repeated dosing of udenafil in the recovery of erectile function in patients with neuronal erectile dysfunction.
根治性前列腺切除术是前列腺癌患者的首选治疗方法。尽管神经保留手术技术已经问世,但手术的成功率并非完全有保障,大多数患者在手术后会出现勃起功能障碍。
本研究旨在探讨新型磷酸二酯酶 5 抑制剂乌地那非重复给药对双侧海绵体神经切除(BCNR)诱导的大鼠阴茎缺氧和纤维化的影响。
本研究使用了 30 只雄性 Sprague-Dawley 大鼠(300-320g)。将动物分为三组;I 组为假手术组(N=10),II 组仅行 BCNR(N=10),III 组在 BCNR 后每日口服 10mg/kg 乌地那非两次,共 8 周(N=10)。
检测阴茎组织中转化生长因子-β1、缺氧诱导因子-1α、内皮型一氧化氮合酶、神经元型一氧化氮合酶和内皮素 B 受体的基因表达。此外,还检测了阴茎勃起功能(通过阴茎海绵体内压(ICP)测量)和海绵体组织的病理变化。
与假手术组相比,II 组的纤维化、细胞凋亡以及 TGF-β1、HIF-1α 和 ET(B)的表达显著增加,而 eNOS 和 nNOS 的表达显著降低,而乌地那非重复给药则显著改善了这些变化。单独行 BCNR 的动物勃起功能明显受损,而乌地那非治疗显著改善了 ICP 测量的勃起功能。
这些结果表明,长期给予乌地那非可改善海绵体神经切除引起的阴茎缺氧和纤维化。本研究还提示重复给予乌地那非可能有助于恢复神经源性勃起功能障碍患者的勃起功能。